Daiwa Securities Group
RPRX icon

Daiwa Securities Group’s Royalty Pharma RPRX Stock Holding History

Daiwa Securities Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42M Buy
749,033
+707,206
+1,691% +$36.8M 0.08% 136
2026
Q1 		$2.01M Buy
41,827
+5,529
+15% +$242K 0.01% 648
2025
Q4 		$1.4M Buy
36,298
+3,210
+10% +$122K ﹤0.01% 727
2025
Q3 		$1.17M Buy
33,088
+1,192
+4% +$43.2K ﹤0.01% 741
2025
Q2 		$1.15M Buy
31,896
+50
+0.2% +$1.66K ﹤0.01% 724
2025
Q1 		$991K Buy
31,846
+1,350
+4% +$42.8K ﹤0.01% 728
2024
Q4 		$778K Sell
30,496
-198
-0.6% -$5.25K ﹤0.01% 764
2024
Q3 		$868K Buy
30,694
+3,000
+11% +$83.1K ﹤0.01% 751
2024
Q2 		$730K Buy
27,694
+1,180
+4% +$32.7K ﹤0.01% 764
2024
Q1 		$805K Sell
26,514
-10,129
-28% -$299K ﹤0.01% 759
2023
Q4 		$1.03M Buy
36,643
+4,007
+12% +$110K 0.01% 692
2023
Q3 		$886K Sell
32,636
-350
-1% -$10.4K 0.01% 704
2023
Q2 		$1.01M Buy
32,986
+1,588
+5% +$53.8K 0.01% 661
2023
Q1 		$1.13M Buy
31,398
+371
+1% +$13.8K 0.01% 631
2022
Q4 		$1.23M Buy
31,027
+1,859
+6% +$77.6K 0.01% 597
2022
Q3 		$1.17M Buy
29,168
+162
+0.6% +$6.92K 0.01% 594
2022
Q2 		$1.22M Buy
29,006
+1,211
+4% +$49.6K 0.01% 591
2022
Q1 		$1.08M Buy
27,795
+9,566
+52% +$376K 0.01% 680
2021
Q4 		$726K Buy
18,229
+399
+2% +$15.5K ﹤0.01% 784
2021
Q3 		$644K Buy
17,830
+1,250
+8% +$48.6K ﹤0.01% 787
2021
Q2 		$680K Buy
16,580
+1,019
+7% +$43.3K ﹤0.01% 751
2021
Q1 		$679K Sell
15,561
-1,539
-9% -$73K 0.01% 728
2020
Q4 		$856K Buy
17,100
+2,866
+20% +$122K 0.01% 612
2020
Q3 		$599K Buy
+14,234
New +$611K 0.01% 642

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Daiwa Securities Group's RPRX Position: Q2 2026 in Review

Daiwa Securities Group increased its Royalty Pharma (RPRX) stake by 1,691% in Q2 2026, buying an estimated $36.8M and bringing the position to 749,033 shares worth $42M. The position accounts for 0.08% of the portfolio, ranked #136.

Daiwa Securities Group first reported a position in RPRX in Q3 2020 and has held it in 24 quarters since. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Daiwa Securities Group held 749,033 shares of Royalty Pharma worth $42M as of Q2 2026.
  • Daiwa Securities Group bought 707,206 Royalty Pharma shares in Q2 2026, an estimated $36.8M.
  • Royalty Pharma made up 0.08% of Daiwa Securities Group's portfolio in Q2 2026, its #136 holding.
  • Daiwa Securities Group first reported a position in Royalty Pharma in Q3 2020 and has held it in 24 quarters since.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Daiwa Securities Group's 13F filing for Q2 2026, filed 31 Jul 2026.